Skip to main content
Erschienen in: Wiener klinische Wochenschrift 1/2019

12.04.2019 | leitlinien für die praxis

Diabetes mellitus – Definition, Klassifikation, Diagnose, Screening und Prävention (Update 2019)

verfasst von: Jürgen Harreiter, Univ. Prof. Dr. DDr. h.c. Michael Roden

Erschienen in: Wiener klinische Wochenschrift | Sonderheft 1/2019

Einloggen, um Zugang zu erhalten

Zusammenfassung

Diabetes mellitus bezeichnet eine Gruppe von heterogenen Erkrankungen, deren gemeinsamer Befund die Erhöhung der Blutglukosekonzentration ist. Die gegenwärtige Klassifikation des Diabetes mellitus wird dargestellt, und die wesentlichen Merkmale von Typ-1- und Typ-2-Diabetes werden gegenübergestellt. Darüber hinaus werden die Kriterien für die korrekte biochemische Diagnose unter Nüchternbedingungen und im oralen Glukosetoleranztest sowie die Anwendung des Hämoglobin A1c (HbA1c) zusammengefasst. Die zunehmende Prävalenz des Diabetes erfordert zudem gezieltes Screening zur Erkennung von Diabetes und Prädiabetes in Risikogruppen. Dies bildete die Grundlage für die frühzeitige Einleitung von Maßnahmen zur Prävention der Manifestation des Diabetes in diesen Risikogruppen und Verzögerung der Diabetesprogression.
Literatur
2.
Zurück zum Zitat Schmutterer I, Delcour J, Griebler R, Hrsg. Österreichischer Diabetesbericht 2017. Wien: Bundesministerium für Gesundheit und Frauen; 2017. Schmutterer I, Delcour J, Griebler R, Hrsg. Österreichischer Diabetesbericht 2017. Wien: Bundesministerium für Gesundheit und Frauen; 2017.
3.
Zurück zum Zitat Huang Y, Cai X, Mai W, Li M, Hu Y. Association between prediabetes and risk of cardiovascular disease and all cause mortality: Systematic review and meta-analysis. BMJ. 2016;i5953:355. Huang Y, Cai X, Mai W, Li M, Hu Y. Association between prediabetes and risk of cardiovascular disease and all cause mortality: Systematic review and meta-analysis. BMJ. 2016;i5953:355.
6.
Zurück zum Zitat Ahlqvist E, Storm P, Karajamaki A, et al. Novel subgroups of adult-onset diabetes and their association with outcomes: A data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol. 2018;6(5):361–9.CrossRef Ahlqvist E, Storm P, Karajamaki A, et al. Novel subgroups of adult-onset diabetes and their association with outcomes: A data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol. 2018;6(5):361–9.CrossRef
7.
Zurück zum Zitat Colagiuri S. Glycated haemoglobin (HbA1c) for the diagnosis of diabetes mellitus—practical implications. Diabetes Res Clin Pract. 2011;93(3):312–3.CrossRef Colagiuri S. Glycated haemoglobin (HbA1c) for the diagnosis of diabetes mellitus—practical implications. Diabetes Res Clin Pract. 2011;93(3):312–3.CrossRef
8.
Zurück zum Zitat Roden M. Diabetes mellitus: Definition, classification and diagnosis. Wien Klin Wochenschr. 2012;124(Suppl 2):1–3.CrossRef Roden M. Diabetes mellitus: Definition, classification and diagnosis. Wien Klin Wochenschr. 2012;124(Suppl 2):1–3.CrossRef
9.
Zurück zum Zitat Kowall B, Rathmann W. HbA1c for diagnosis of type 2 diabetes. Is there an optimal cut point to assess high risk of diabetes complications, and how well does the 6.5% cutoff perform? Diabetes Metab Syndr Obes. 2013;6:477–91.CrossRef Kowall B, Rathmann W. HbA1c for diagnosis of type 2 diabetes. Is there an optimal cut point to assess high risk of diabetes complications, and how well does the 6.5% cutoff perform? Diabetes Metab Syndr Obes. 2013;6:477–91.CrossRef
11.
Zurück zum Zitat European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL–EASD–EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. Diabetologia. 2016;59(6):1121–40.CrossRef European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL–EASD–EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. Diabetologia. 2016;59(6):1121–40.CrossRef
13.
Zurück zum Zitat Kowall B, Rathmann W, Strassburger K, et al. Association of passive and active smoking with incident type 2 diabetes in the elderly population: The KORA S4/F5 cohort study. Eur J Epidemiol. 2010;25(6):393–402.CrossRef Kowall B, Rathmann W, Strassburger K, et al. Association of passive and active smoking with incident type 2 diabetes in the elderly population: The KORA S4/F5 cohort study. Eur J Epidemiol. 2010;25(6):393–402.CrossRef
14.
Zurück zum Zitat Haw JS, Galaviz KI, Straus AN, et al. Long-term sustainability of diabetes prevention approaches: A systematic review and meta-analysis of randomized clinical trials. JAMA Intern Med. 2017;177(12):1808–17.CrossRef Haw JS, Galaviz KI, Straus AN, et al. Long-term sustainability of diabetes prevention approaches: A systematic review and meta-analysis of randomized clinical trials. JAMA Intern Med. 2017;177(12):1808–17.CrossRef
15.
Zurück zum Zitat Glechner A, Harreiter J, Gartlehner G, et al. Sex-specific differences in diabetes prevention: A systematic review and meta-analysis. Diabetologia. 2015;58(2):242–54.CrossRef Glechner A, Harreiter J, Gartlehner G, et al. Sex-specific differences in diabetes prevention: A systematic review and meta-analysis. Diabetologia. 2015;58(2):242–54.CrossRef
17.
Zurück zum Zitat Li G, Zhang P, Wang J, et al. Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: A 23-year follow-up study. Lancet Diabetes Endocrinol. 2014;2(6):474–80.CrossRef Li G, Zhang P, Wang J, et al. Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: A 23-year follow-up study. Lancet Diabetes Endocrinol. 2014;2(6):474–80.CrossRef
18.
Zurück zum Zitat Panunzi S, De Gaetano A, Carnicelli A, Mingrone G. Predictors of remission of diabetes mellitus in severely obese individuals undergoing bariatric surgery: Do BMI or procedure choice matter? A meta-analysis. Ann Surg. 2015;261(3):459–67.CrossRef Panunzi S, De Gaetano A, Carnicelli A, Mingrone G. Predictors of remission of diabetes mellitus in severely obese individuals undergoing bariatric surgery: Do BMI or procedure choice matter? A meta-analysis. Ann Surg. 2015;261(3):459–67.CrossRef
19.
Zurück zum Zitat Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393–403.CrossRef Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393–403.CrossRef
20.
Zurück zum Zitat Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344(18):1343–50.CrossRef Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344(18):1343–50.CrossRef
21.
Zurück zum Zitat Li G, Zhang P, Wang J, et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing diabetes prevention study: A 20-year follow-up study. Lancet. 2008;371(9626):1783–9.CrossRef Li G, Zhang P, Wang J, et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing diabetes prevention study: A 20-year follow-up study. Lancet. 2008;371(9626):1783–9.CrossRef
22.
Zurück zum Zitat Ramachandran A, Snehalatha C, Mary S, et al. The Indian diabetes prevention programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia. 2006;49(2):289–97.CrossRef Ramachandran A, Snehalatha C, Mary S, et al. The Indian diabetes prevention programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia. 2006;49(2):289–97.CrossRef
23.
Zurück zum Zitat Roumen C, Corpeleijn E, Feskens EJ, et al. Impact of 3‑year lifestyle intervention on postprandial glucose metabolism: The SLIM study. Diabet Med. 2008;25(5):597–605.CrossRef Roumen C, Corpeleijn E, Feskens EJ, et al. Impact of 3‑year lifestyle intervention on postprandial glucose metabolism: The SLIM study. Diabet Med. 2008;25(5):597–605.CrossRef
24.
Zurück zum Zitat Penn L, White M, Oldroyd J, et al. Prevention of type 2 diabetes in adults with impaired glucose tolerance: The European diabetes prevention RCT in Newcastle upon Tyne, UK. BMC Public Health. 2009;9:342.CrossRef Penn L, White M, Oldroyd J, et al. Prevention of type 2 diabetes in adults with impaired glucose tolerance: The European diabetes prevention RCT in Newcastle upon Tyne, UK. BMC Public Health. 2009;9:342.CrossRef
25.
Zurück zum Zitat Saito T, Watanabe M, Nishida J, et al. Lifestyle modification and prevention of type 2 diabetes in overweight Japanese with impaired fasting glucose levels: A randomized controlled trial. Arch Intern Med. 2011;171(15):1352–60.CrossRef Saito T, Watanabe M, Nishida J, et al. Lifestyle modification and prevention of type 2 diabetes in overweight Japanese with impaired fasting glucose levels: A randomized controlled trial. Arch Intern Med. 2011;171(15):1352–60.CrossRef
26.
Zurück zum Zitat Sakane N, Sato J, Tsushita K, et al. Prevention of type 2 diabetes in a primary healthcare setting: Three-year results of lifestyle intervention in Japanese subjects with impaired glucose tolerance. BMC Public Health. 2011;11(1):40.CrossRef Sakane N, Sato J, Tsushita K, et al. Prevention of type 2 diabetes in a primary healthcare setting: Three-year results of lifestyle intervention in Japanese subjects with impaired glucose tolerance. BMC Public Health. 2011;11(1):40.CrossRef
27.
Zurück zum Zitat The American Diabetes Association (ADA). 5. Prevention or delay of type 2 diabetes: Standards of medical care in diabetes–2018. Diabetes Care. 2018;41(Suppl 1):S51–S4.CrossRef The American Diabetes Association (ADA). 5. Prevention or delay of type 2 diabetes: Standards of medical care in diabetes–2018. Diabetes Care. 2018;41(Suppl 1):S51–S4.CrossRef
28.
Zurück zum Zitat Bian RR, Piatt GA, Sen A, et al. The effect of technology-mediated diabetes prevention interventions on weight: A meta-analysis. J Med Internet Res. 2017;19(3):e76.CrossRef Bian RR, Piatt GA, Sen A, et al. The effect of technology-mediated diabetes prevention interventions on weight: A meta-analysis. J Med Internet Res. 2017;19(3):e76.CrossRef
29.
Zurück zum Zitat The American Diabetes Association (ADA). 4. Lifestyle management: Standards of medical care in diabetes–2018. Diabetes Care. 2018;41(Suppl 1):S38–S50.CrossRef The American Diabetes Association (ADA). 4. Lifestyle management: Standards of medical care in diabetes–2018. Diabetes Care. 2018;41(Suppl 1):S38–S50.CrossRef
30.
Zurück zum Zitat Afshin A, Micha R, Khatibzadeh S, Mozaffarian D. Consumption of nuts and legumes and risk of incident ischemic heart disease, stroke, and diabetes: A systematic review and meta-analysis. Am J Clin Nutr. 2014;100(1):278–88.CrossRef Afshin A, Micha R, Khatibzadeh S, Mozaffarian D. Consumption of nuts and legumes and risk of incident ischemic heart disease, stroke, and diabetes: A systematic review and meta-analysis. Am J Clin Nutr. 2014;100(1):278–88.CrossRef
31.
Zurück zum Zitat Mozaffarian D. Dietary and policy priorities for cardiovascular disease, diabetes, and obesity: A comprehensive review. Circulation. 2016;133(2):187–225.CrossRef Mozaffarian D. Dietary and policy priorities for cardiovascular disease, diabetes, and obesity: A comprehensive review. Circulation. 2016;133(2):187–225.CrossRef
32.
Zurück zum Zitat Mursu J, Virtanen JK, Tuomainen TP, Nurmi T, Voutilainen S. Intake of fruit, berries, and vegetables and risk of type 2 diabetes in Finnish men: The Kuopio ischaemic heart disease risk factor study. Am J Clin Nutr. 2014;99(2):328–33.CrossRef Mursu J, Virtanen JK, Tuomainen TP, Nurmi T, Voutilainen S. Intake of fruit, berries, and vegetables and risk of type 2 diabetes in Finnish men: The Kuopio ischaemic heart disease risk factor study. Am J Clin Nutr. 2014;99(2):328–33.CrossRef
33.
Zurück zum Zitat Chen M, Sun Q, Giovannucci E, et al. Dairy consumption and risk of type 2 diabetes: 3 cohorts of US adults and an updated meta-analysis. BMC Med. 2014;12:215.CrossRef Chen M, Sun Q, Giovannucci E, et al. Dairy consumption and risk of type 2 diabetes: 3 cohorts of US adults and an updated meta-analysis. BMC Med. 2014;12:215.CrossRef
34.
Zurück zum Zitat Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials. Lancet. 2010;375(9716):735–42.CrossRef Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials. Lancet. 2010;375(9716):735–42.CrossRef
35.
Zurück zum Zitat Abuissa H, Jones PG, Marso SP, O’Keefe JH Jr.. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: A meta-analysis of randomized clinical trials. J Am Coll Cardiol. 2005;46(5):821–6.CrossRef Abuissa H, Jones PG, Marso SP, O’Keefe JH Jr.. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: A meta-analysis of randomized clinical trials. J Am Coll Cardiol. 2005;46(5):821–6.CrossRef
36.
Zurück zum Zitat Zinman B, Harris SB, Neuman J, et al. Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): A double-blind randomised controlled study. Lancet. 2010;376(9735):103–11.CrossRef Zinman B, Harris SB, Neuman J, et al. Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): A double-blind randomised controlled study. Lancet. 2010;376(9735):103–11.CrossRef
37.
Zurück zum Zitat Lindblad U, Lindberg G, Mansson NO, et al. Can sulphonylurea addition to lifestyle changes help to delay diabetes development in subjects with impaired fasting glucose? The Nepi ANtidiabetes StudY (NANSY). Diabetes Obes Metab. 2011;13(2):185–8.CrossRef Lindblad U, Lindberg G, Mansson NO, et al. Can sulphonylurea addition to lifestyle changes help to delay diabetes development in subjects with impaired fasting glucose? The Nepi ANtidiabetes StudY (NANSY). Diabetes Obes Metab. 2011;13(2):185–8.CrossRef
38.
Zurück zum Zitat DeFronzo RA, Tripathy D, Schwenke DC, et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med. 2011;364(12):1104–15.CrossRef DeFronzo RA, Tripathy D, Schwenke DC, et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med. 2011;364(12):1104–15.CrossRef
39.
Zurück zum Zitat Investigators DT, Gerstein HC, Yusuf S, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: A randomised controlled trial. Lancet. 2006;368(9541):1096–105.CrossRef Investigators DT, Gerstein HC, Yusuf S, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: A randomised controlled trial. Lancet. 2006;368(9541):1096–105.CrossRef
40.
Zurück zum Zitat Investigators DT, Bosch J, Yusuf S, et al. Effect of ramipril on the incidence of diabetes. N Engl J Med. 2006;355(15):1551–62.CrossRef Investigators DT, Bosch J, Yusuf S, et al. Effect of ramipril on the incidence of diabetes. N Engl J Med. 2006;355(15):1551–62.CrossRef
41.
Zurück zum Zitat Chiasson JL, Josse RG, Gomis R, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: The STOP-NIDDM trial. JAMA. 2003;290(4):486–94.CrossRef Chiasson JL, Josse RG, Gomis R, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: The STOP-NIDDM trial. JAMA. 2003;290(4):486–94.CrossRef
42.
Zurück zum Zitat Kawamori R, Tajima N, Iwamoto Y, et al. Voglibose for prevention of type 2 diabetes mellitus: A randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet. 2009;373(9675):1607–14.CrossRef Kawamori R, Tajima N, Iwamoto Y, et al. Voglibose for prevention of type 2 diabetes mellitus: A randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet. 2009;373(9675):1607–14.CrossRef
43.
Zurück zum Zitat Group NS, Holman RR, Haffner SM, et al. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010;362(16):1463–76.CrossRef Group NS, Holman RR, Haffner SM, et al. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010;362(16):1463–76.CrossRef
44.
Zurück zum Zitat Group NS, McMurray JJ, Holman RR, et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010;362(16):1477–90.CrossRef Group NS, McMurray JJ, Holman RR, et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010;362(16):1477–90.CrossRef
45.
Zurück zum Zitat Investigators OT, Gerstein HC, Bosch J, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367(4):319–28.CrossRef Investigators OT, Gerstein HC, Bosch J, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367(4):319–28.CrossRef
46.
Zurück zum Zitat Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27(1):155–61.CrossRef Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27(1):155–61.CrossRef
47.
Zurück zum Zitat Tenenbaum A, Motro M, Fisman EZ, et al. Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients. Eur Heart J. 2005;26(19):2032–8.CrossRef Tenenbaum A, Motro M, Fisman EZ, et al. Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients. Eur Heart J. 2005;26(19):2032–8.CrossRef
48.
Zurück zum Zitat Insel R, Dunne JL. JDRF’s vision and strategy for prevention of type 1 diabetes. Pediatr Diabetes. 2016;17(Suppl 22):87–92.CrossRef Insel R, Dunne JL. JDRF’s vision and strategy for prevention of type 1 diabetes. Pediatr Diabetes. 2016;17(Suppl 22):87–92.CrossRef
49.
Zurück zum Zitat Hober D, Alidjinou EK. Diabetes: Towards a coxsackievirus B‑based vaccine to combat T1DM. Nat Rev Endocrinol. 2018;14(3):131–2.CrossRef Hober D, Alidjinou EK. Diabetes: Towards a coxsackievirus B‑based vaccine to combat T1DM. Nat Rev Endocrinol. 2018;14(3):131–2.CrossRef
50.
Zurück zum Zitat Deutsche Diabetes Gesellschaft (DDG). Diagnostik, Therapie und Verlaufskontrolle des Diabetes mellitus im Kindes- und Jugendalter – S3-Leitlinie der DDG und AGPD 2015. 2015. Deutsche Diabetes Gesellschaft (DDG). Diagnostik, Therapie und Verlaufskontrolle des Diabetes mellitus im Kindes- und Jugendalter – S3-Leitlinie der DDG und AGPD 2015. 2015.
51.
Zurück zum Zitat Vaarala O, Klemetti P, Juhela S, et al. Effect of coincident enterovirus infection and cows’ milk exposure on immunisation to insulin in early infancy. Diabetologia. 2002;45(4):531–4.CrossRef Vaarala O, Klemetti P, Juhela S, et al. Effect of coincident enterovirus infection and cows’ milk exposure on immunisation to insulin in early infancy. Diabetologia. 2002;45(4):531–4.CrossRef
52.
Zurück zum Zitat Monetini L, Cavallo MG, Stefanini L, et al. Bovine beta-casein antibodies in breast- and bottle-fed infants: Their relevance in type 1 diabetes. Diabetes Metab Res Rev. 2001;17(1):51–4.CrossRef Monetini L, Cavallo MG, Stefanini L, et al. Bovine beta-casein antibodies in breast- and bottle-fed infants: Their relevance in type 1 diabetes. Diabetes Metab Res Rev. 2001;17(1):51–4.CrossRef
53.
Zurück zum Zitat Ziegler AG, Schmid S, Huber D, Hummel M, Bonifacio E. Early infant feeding and risk of developing type 1 diabetes-associated autoantibodies. JAMA. 2003;290(13):1721–8.CrossRef Ziegler AG, Schmid S, Huber D, Hummel M, Bonifacio E. Early infant feeding and risk of developing type 1 diabetes-associated autoantibodies. JAMA. 2003;290(13):1721–8.CrossRef
54.
Zurück zum Zitat Norris JM, Barriga K, Klingensmith G, et al. Timing of initial cereal exposure in infancy and risk of islet autoimmunity. JAMA. 2003;290(13):1713–20.CrossRef Norris JM, Barriga K, Klingensmith G, et al. Timing of initial cereal exposure in infancy and risk of islet autoimmunity. JAMA. 2003;290(13):1713–20.CrossRef
Metadaten
Titel
Diabetes mellitus – Definition, Klassifikation, Diagnose, Screening und Prävention (Update 2019)
verfasst von
Jürgen Harreiter
Univ. Prof. Dr. DDr. h.c. Michael Roden
Publikationsdatum
12.04.2019
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe Sonderheft 1/2019
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-019-1450-4

Weitere Artikel der Sonderheft 1/2019

Wiener klinische Wochenschrift 1/2019 Zur Ausgabe